

Index

Note: page numbers in *italics* refer to figures, those in **bold** refer to tables.

- abdominal circumference, fetal 286–287
- abdominal wall closure techniques 383
- ABO incompatibility 448
- abortion, spontaneous 253–259
 - amniocentesis 411
 - anthropomorphic factors 257–258
 - antiphospholipid antibodies 124–125, 256–257
 - chorionic villus sampling 413–414
 - early in inherited thrombophilia 125–126
 - endocrinopathies 254–255
 - epilepsy 203–204
 - genetic abnormalities 253–254
 - immunologic causes 257
 - infections 254
 - inherited thrombophilias 125–126, 255–256
 - procedure-induced 411, 413–414, 422–423
 - social factors 257–258
 - syphilis 225
 - uterine abnormalities 255
- abruptio placentae
 - eclampsia 278
 - fetal hemorrhage 444
 - inherited thrombophilia 125
 - multiple pregnancy 308
 - preterm delivery 335
 - preterm premature rupture of the membranes 346
- α -cells, fetal 89
- acetaminophen 49–50
- acetylcholinesterase screen 70
- acyclovir 51–52
 - herpes simplex virus 228–229
 - during pregnancy 169
- acid–base status
 - normal 105
 - see also* metabolic acidosis
- activated protein C (APC) 121, 134
- acute fatty liver of pregnancy 309
- adrenal gland, fetal 85–86
 - fetal adrenal zone development 334
- adrenocorticotrophic hormone (ACTH) 82, 84, 86
- alcohol abuse 24, 25, 26–30
 - fetal effects 24, 25, 26
 - postpartum care 29–30
 - pregnancy management 26–27
 - prenatal care 27, 28–29, 29
- aldosterone 163
- alkylating agents, teratogens 43
- alpha-fetoprotein
 - maternal screening 67–69, 70, 71
 - combined first/second trimester 76
 - second trimester 75–76
 - multiple pregnancy 310
 - placenta accreta diagnosis 368
- amniocentesis 70, 91
 - congenital infections 419
 - cytogenetics 415
 - diagnostic studies 415–416
 - DNA analysis 416
 - early 411
 - enzymatic analysis 416
 - genetic testing 409–411
 - miscarriage 411
 - multiple pregnancy 310, 410, 411
 - polyhydramnios 321
 - pregnancy loss risk 411
 - prematurity evaluation 354
 - prior to cordocentesis 420
 - safety 410–411
 - technique 409–410
 - traditional 409–411
 - ultrasound 409, 411
- amnioinfusion 425–431
 - administration route 425
 - amount infused 425
 - chorioamnionitis 425, 426–427
 - complications 429
 - deceleration prevention in PPRM 427–428
 - indications 426, **431**
 - meconium-stained amniotic fluid 428–429, **430**
 - oligohydramnios 322, 323, 425, 426, 427, **428**, 431
 - prophylactic in labor 427, **428**
 - transabdominal 322, 323, 427
 - transcervical 425
 - variable deceleration relief 426
- amnionitis 346
- amniotic fluid
 - anencephaly 318
 - aspiration 410
 - clinical measurement 319
 - composition 316
 - intramembranous flow 318
 - meconium-stained 428–429, **430**
 - recirculation 318–319
 - single deepest pocket measurement 319, 377
 - techniques for obtaining 91
 - turnover dynamics 316–319
 - volume 316, 376
 - polyhydramnios 320
 - subjective assessment 319
 - see also* oligohydramnios; polyhydramnios
- amniotic fluid embolism (AFE) 280–281
 - plasma products 282–283
 - recombinant factor VIIA 283
- amniotic fluid index (AFI) 95, 96–97, 101
 - measurement 319
 - mild preeclampsia 273
 - oligohydramnios 321
 - polyhydramnios 320
 - prolonged pregnancy 377
- ampicillin 51, 234, **235**
- preterm labor 359
- resistance 234
- analgesia/analgesics 49–50, 401–404
 - combined spinal–epidural 402
 - multimodal 401–402
 - postoperative 404
 - regional 401–402
 - side-effects 402
- anaphylactoid syndrome of pregnancy 280
- androgens
 - resistance 84
 - teratogenicity 44

- anemia
 fetal 223, 420
 iron deficiency 14, 15–16
 neonatal 444–445
see also hemolytic disease of the newborn
- anencephaly 67
 alpha-fetoprotein maternal screening 68–69
- amniotic fluid excess 318
 fetal swallowing 318
- anesthesia 401
 regional
 cesarean delivery 403–404
 fetoscopic surgery 438
- aneuploidy, fetal 72–77
 advanced maternal age-related 253–254
 combined first and second trimester screening 76–77
 heritable factors 254
 minor markers 75
 multiple pregnancy 310
 screening 310
 second trimester
 serum screening 75–76
 sonographic screening 75
 spontaneous abortion 253
 structural malformations 75
- angiotensin converting enzyme (ACE)
 gene polymorphism 127
- angiotensin converting enzyme (ACE)
 inhibitors
 contraindications 170–171, 210
 renal insufficiency 165–166
 teratogenicity 41, 42–43, 165–166
- angiotensin II 16
- angiotensin receptor blockers 165–166
 contraindications 210
- anhydramnios 322
- antepartum fetal monitoring 95–102
 diagnostic conditions 100–101
 tests 95–99
- antibiotics
 amnioinfusion for chorioamnionitis 426–427
 cervical incompetence management 267, 268
 preterm birth 329
 preterm labor 356
 prophylactic
 cesarean delivery 383
 cordocentesis 420
 toxicity 51
- anticardiolipin antibodies 125, 217, 218
 spontaneous abortion 257
- anticoagulant system 119
- anticoagulants
 endogenous 134
 mechanical heart valve anticoagulation 149–151
 pharmacology 127–129
 spontaneous abortion prevention 256
- anticonvulsants, fetal
 syndrome 201–203
- anti-D antibody 299
- anti-D immunoglobulin 114
- antidepressants 48–49
- antidiuretic hormone (ADH) 83, 84, 163–164
- antiepileptic drugs 201
 breastfeeding 206
 clearance 204–205
 contraception with 201, 202
 fetal syndrome 201–203
 management 204–205
 monotherapy 202–203, 206
 neonatal vitamin K deficiency 205
 postpartum 206
 prenatal screening 203
 teratogenicity 43, 201–204
- antihistamines 50–51
- antihypertensive drugs 50, 211–212
 preeclampsia
 postpartum management 275
 severe 274
 teratogenicity 42–43
- antimetabolites, teratogenicity 44–45
- antinuclear antibody (ANA) 214
- antiphospholipid antibodies (APA) 123, 124–125, 218–219
 spontaneous abortion 256–257
 systemic lupus erythematosus 214, 217
- antiphospholipid antibody syndrome 49, 217, 218, 219, 220
- antiretroviral drugs 243, 244–247, 247–248
- anti-SSA/Ro antibodies 217
- anti-SSB/La antibodies 217
- antithrombin 121–122, 134
 deficiency 119–120, 122, 129
- antithrombin III (AT-III) 129
- antithyroid drugs, teratogenicity 45
- antiviral drugs 51–52
- anxiety, maternal 333
- aortic aneurysm rupture 151
- aortic coarctation, maternal 151
- aortic dissection, Marfan syndrome 153
- aortic regurgitation, maternal 148
- aortic root dissection, Marfan syndrome 153
- aortic stenosis 149
- arachidonic acid 449
- arginine vasotocin (AVT) 83
- Arnold–Chiari II malformation 69
 open fetal surgery 436
- arterial blood gases, pulmonary embolism 137
- Asherman syndrome 255
- aspirin 49–50
 mechanical heart valve patients 151
 spontaneous abortion prevention 256
 systemic lupus erythematosus 219, 220
 thrombophilia 127
- assisted reproduction 3, 4
- asthma 192–199
 acute 197–198
 assessment 194
 chronic 196–197
 delivery 198
 diagnosis 194
 effects on pregnancy 192–194
 fetal monitoring 197–198
 inadequate control 193
- labor 198
 management 194–198
 patient education 195–196
 pharmacologic therapy 196–198
 severity 193, 194–195
- atherosclerosis, heart transplantation 172, 174
- atosiban 359
- atrial fibrillation 158
 maternal 148
- atrial septal defect, maternal 152
- autosomal disorders
 dominant 61–62
 recessive 61, 62
- azathioprine 156, 158, 170
- bacterial vaginosis 254
 preterm delivery 334
- bacteriuria
 sickle cell disease 110
 streptococci group B 235
- basiliximab 170
- β -cells, fetal 88–89
- bed rest
 multiple pregnancy 311
 preterm labor 356
- behavioral therapy, substance abuse 26
- benzene 34
- benzodiazepines 48
- beta agonists 105, 198
- beta-adrenergic agents 198
- betamethasone 47–48, 355
 fetal maturation 355
- Bifidobacterium* 18
- bilirubin
 fetal 301
 neonatal jaundice 447–448, 449
- biophysical profile 3, 4, 95, 97, 98, 99, 101
 IUGR 292, 293
 maternal hypertension 212
 prolonged pregnancy 376
 score deterioration 292
- birth asphyxia 456
- birth weight
 cigarette smoking 13
 energy/protein supplementation 14
 famine conditions 10
 neonatal deaths 442
 preeclampsia 7
 repeat tendency 8
 trial of labor 390
see also low birthweight; very low birthweight
- blastocyst, mosaic 416
- blood gases
 asthma 197
 pulmonary embolism 137
- blood loss
 cesarean delivery 15
 iatrogenic neonatal 445
 placenta accreta surgery 368
 placenta manual removal 383
 placenta previa 364
 vasa previa 365–366
see also hemorrhage
- blood pressure
 pregnancy 143, 163
see also hypertension, maternal

- blood product replacement 280, 282–283
- blood sampling, direct fetal 419–423
- blood volume in pregnancy 143, 144
- body mass index (BMI) 6, 9
- prepregnancy 10–11, 20
- preterm delivery 10
- bone turnover, lactation/pregnancy 16
- bradycardia, transient fetal 422
- brain imaging in neonatal encephalopathy 455
- brain injury, fetal hypoxic 391–392
- brain-sparing reflex 290, 291, 292
- breastfeeding 449–450
- antiepileptic drugs 206
- benefits 18–19
- contraindications 450
- HIV infection 248
- medications 48, 49, 50, 51, 52
- teratogens 42–43, 44, 45, 46, 47
- rubella infection 224
- transplantation patients 174
- breastmilk
- composition 19
- drug concentrations 42
- environmental agents 42
- expressed 450
- nutritional quality 19
- properties 449–450
- volume 19
- breastmilk jaundice 448, 450
- breech delivery 397–400
- labor management 399
- vaginal 397–398, 400
- selection criteria 398–399
- technique 399
- breech presentation 385–386
- blood loss 445
- cesarean delivery 399–400
- epidemiology 397
- external cephalic version 397, 427
- calcium
- fetal levels 16
- requirements in pregnancy 12, 14, 15, 16
- supplementation 16
- calcium-channel blockers 105, 171
- hypertension therapy 211, 212
- preterm labor 357
- renal insufficiency 166
- Canavan disease 63, 64
- captopril 42–43
- carbamazepine
- neural tube defects 17, 202
- teratogenicity 43, 203
- carbohydrate, dietary 177
- carbohydrate intolerance 176
- cardiac abnormalities
- fetal malformations 75
- fetal risk 146
- maternal congenital 151–153
- cardiac afterload, peripartum
- cardiomyopathy 154
- cardiac arrest, cesarean delivery 284
- cardiac arrhythmias, maternal 156
- cardiac contractility, peripartum
- cardiomyopathy 154
- cardiac disease, New York Heart Association classification 143–145
- cardiac disease, maternal 143–159
- counseling 143–146
- fetal cardiac abnormality risk 146
- maternal mortality 143, 145, 149, 151, 152
- valvular heart disease 146–151
- cardiac dysfunction, sickle cell disease 110
- cardiac function, pregnancy changes 143, 144
- cardiac output
- early gestation 38
- mitral stenosis 147
- pregnancy 143, 144, 149
- cardiac physiology, maternal 7
- cardiac preload, peripartum
- cardiomyopathy 154
- cardiogenic shock, amniotic fluid embolism 280
- cardiomyopathy, peripartum 153–155
- cardiovascular drugs 157–158
- cardiovascular failure, amniotic fluid embolism 280
- carotid artery ligation 447
- carrier screening 62–64
- case-control surveillance, teratogens 41–42
- catheter vesicoamniotic shunt 439
- CD4 counts 243, 249
- cephalohematoma 444–445
- neonatal jaundice 448
- cephalosporins 51
- cerclage, cervical 266
- complications 267
- management after 267
- multiple pregnancy 310–311
- preterm birth prevention 328–329
- preterm premature rupture of the membranes 350
- prophylactic 264–265, 310–311
- cerebral blood flow, fetal 290
- cerebral palsy 452–454
- multiple pregnancy 304–305
- cervix
- dysplasia treatment procedures 265
- examination 354
- trial of labor 391
- favourability in prolonged pregnancy 377
- length surveillance 311, 337–338
- prematurity assessment 355
- shortening 311, 328–329, 337–338
- see also cerclage, cervical
- cervix, incompetent 263–268
- biologic continuum 263
- diagnosis 263–264
- management 264–265
- adjunctive strategies 267–268
- risk factors 265
- sonographic diagnosis 265–266
- cesarean delivery 382–387
- 5-minute rule 284
- abdominal wall closure 383
- anesthesia 403–404
- antibiotic prophylaxis 383
- anticoagulation management 151
- blood loss 15
- breech presentation 397–398, 399–400
- diabetes mellitus 184
- eclampsia 278
- evidence-based operative considerations 382–383
- fetal distress 385
- gestational diabetes 179
- HELLP syndrome 277
- HIV infection 248
- hysterotomy closure 383
- indications 385–386
- malpresentation of fetus 385–386
- maternal morbidity/mortality 382
- multiple pregnancy 312
- multiple prior 391
- perimortem 280, 283–284
- perinatal morbidity/mortality 382
- placenta accreta 367, 368
- placenta manual removal 383
- placenta previa 364, 365
- postoperative analgesia 404
- postoperative endometritis 383
- preeclampsia 275
- preterm labor 359
- prior indication 390
- prolonged pregnancy 377
- rate 384–385
- repeat 384, 386
- thrombocytopenia 116
- thromboembolism risk 135
- thromboprophylaxis 383
- tonic-clonic seizures 205–206
- transplantation patients 173
- uterine incision repair 383
- vasa previa 367
- CFTR gene 64
- chancres 225
- chelation therapy, lead toxicity 33
- chest X-ray
- fetal risk 139–140
- pulmonary embolism 137
- chickenpox 231–232
- Chlamydia trachomatis* (chlamydia) 254
- screening 29
- chorioamnionitis 267, 268
- amnioinfusion 425, 426–427
- prematurity evaluation 354
- preterm birth 329
- preterm premature rupture of the membranes 346, 347
- prophylaxis 426–427
- risk with cordocentesis 420
- treatment 426–427
- chorionic villus sampling 64, 76, 77
- confined placental mosaicism 415–416
- cytogenetics 415
- diagnostic studies 415–416
- DNA analysis 416
- enzymatic analysis 416
- genetic testing 409, 411–417
- limb abnormalities 414–415
- maternal cell contamination 415
- multiple pregnancy 310
- pregnancy loss 413–414
- safety 413–415

- chorionic villus sampling (*cont.*)
 technique 412–413
 transabdominal 412–413
 transcervical 412
- chorionic villus surface area 7
- chorionicity 305–306
- chromosomal anomalies
 multiple pregnancy 309
 oligohydramnios 322
- cigarette smoking, birth weight 13
- ciprofloxacin 51
- circle of Willis, fetal 291
- cleft lip/palate, antiepileptic drug
 exposure 202,203
- clindamycin 234,235
 resistance 234
- clotting factors
 pregnancy 119,135
see also individual factors
- coagulation cascade 283
 disseminated intravascular coagulation
 281
 pregnancy 133–134,143,144
- cocaine use 211
- cognitive outcome, epilepsy 203
- colostrum 449
- combined spinal–epidural analgesia 402
- computed tomography (CT), spiral 138
- congenital adrenal hyperplasia (CAH) 86
- congenital cystoid adenomatoid
 malformation 433,437
- congenital diaphragmatic hernia 437,
 438–439
- congenital malformations
 anticonvulsants 17,202,203
 cardiac
 fetal 75
 maternal 151–153
 developmental pathology 202
 diabetes 182
 fetal anticonvulsant syndrome 201–203
 fetoscopic surgery 437,438–439
 multiple pregnancy 307,309,310
 oligohydramnios 322,427
 polyhydramnios association 320,321
 timing 202
 ultrasound detection 310
see also neural tube defects
- congenital rubella syndrome 224
- connexin 43 334
- contraction stress test (CST) 95,97,98,99
- contraction-associated proteins 334
- convulsions, eclampsia 277,278
- cooling, induced 444
- cord blood studies 456
- cordocentesis 3,4,419–423
 complications 422–423
 congenital infections 419
 fetal anemia 420
 fetal growth restriction acid–base
 balance 420
 fetal platelet count 115–116
 fetal thrombocytopenia 420
 infections 422
 post-procedure monitoring 420
 pregnancy loss 422–423
 quality control 420–421
 sampling procedure 420
 technique 420–421
 twin–twin transfusion syndrome 420
- corticosteroids
 asthma 193,197,198
 fetal maturation 350,355–356
 fetal thrombocytopenia 115
 HELLP syndrome 276
 immunosuppressive action 156
 inhaled 197,198
 oral 197
 systemic 198
- corticotropin-releasing hormone (CRH)
 81,82,84
 fetal stress marker 336
 preterm birth 333–334,336
- coumadin 151
- coumarin derivatives 45
- counseling
 HIV infection 243
 maternal cardiac disease 143–146
 multiple pregnancy 307,309–310
 prepregnancy for transplantation
 patients 168
 preterm premature rupture of the
 membranes 349–350
 substance abuse 27
 vaginal birth after cesarean delivery
 394
- creatinine, serum levels 165,166
 elevated 211
- cromolyn 197
- crow–rump length, fetal 77
 dating of pregnancy 286
- Cushing syndrome 211
- cyclo-oxygenase (COX) inhibitors
 357–358
- cyclophosphamide
 contraindication in pregnancy 218
 premature ovarian failure 217
 teratogen 43
- cyclosporine 156,170,171
- CYP21A2 deficiency 86,89
- cystic fibrosis, carrier screening 62,63,
 64,65
- cystic hygroma 74–75
- cytogenetics
 amniocentesis 415
 chorionic villus sampling 415
 diagnostic 419
- cytomegalovirus (CMV) 229–231
 clinical manifestations 229
 diagnosis 229–230
 management 230–231
 pathogenesis 229
 prevention 230–231
 transmission 229
 transplantation patients 169
- dacliximab 170
- danaparoid 129
- dating of pregnancy 286–287
- D-dimer assays 135–136,137–138
- decidua basalis deficiency 367
- decidual hemorrhage *see* abruptio
 placentae
- decidual tissue factor 119,135
- decidual-amnion-chorion inflammation
 334–335
- deep vein thrombosis (DVT) 133
 clinical risk scoring system 136
 D-dimer assays 135–136
 diagnostic algorithm 135,136
 risk assessment 135
 venous imaging 136
- dehydration, hypernatremic 450
- dehydroepiandrosterone sulfate
 (DHEAS) 86
 fetal adrenal zone production 334
- delivery
 acute myocardial infarction 156
 asthma management 198
 eclampsia 278
 epilepsy 205–206
 gestational diabetes 179
 HELLP syndrome 277
 HIV infection 248
 maternal hypertension 212–213
 multiple pregnancy 312
 placenta previa 364,365
 preeclampsia 275
 preterm labor 359
 sickle cell disease 111
 timing for prolonged pregnancy
 376–378
*see also cesarean delivery; vaginal
 birth after cesarean delivery;
 vaginal delivery*
- delivery room, thermoregulation 443
- dental amalgam 33
- depression, medications 48–49
- dexamethasone 47–48
 fetal maturation 355
- diabetes 182–184
 antenatal testing 178–179
 congenital malformations 182
 evaluation 182–183
 fetal lung maturation delay 93
 gestational 176–180
 delivery 179
 glucose testing 177–178
 postpartum care 179
 treatment 177–178
 insulin-dependent 182
 perinatal mortality 182
 polyhydramnios association 320,
 321
 preconception care 182
 preconceptual 17
 screening in pregnancy 176–177
 White's classification 183
- diaphragmatic hernia 437,438–439
- diazepam 48
- dichorionicity 304
 fetal complications 307
- diet, maternal
 gestational diabetes 177
 quantity/quality 8
see also nutrition, maternal
- dietary recommendations 19–20
- diethylstilbestrol 44
in utero exposure 265
- 1,25-dihydroxycholecalciferol 16
- diphenhydramine 50–51
- disomy, uniparental 416
- disseminated intravascular coagulation
 (DIC) 114,280,281–282

- multiple pregnancy 308
- recombinant factor VIIa 283
- diuresis, cardiac disease 154, 158
- diuretics, nephrotic syndrome 164
- dizygotic twins 305
 - maternal age 309
- DNA analysis 416
 - fetal blood typing 300
- docosahexaenoic acid (DHA) 449
- Doppler imaging 299–300
 - arterial 291
 - DVT 136
 - fetal
 - arterial 290–291, 293
 - clinical application 292–293
 - intrauterine growth restriction 289–293
 - middle cerebral artery 223, 290–291, 299–300
 - venous 291, 292, 293
 - multiple pregnancy 311
 - placenta accreta diagnosis 368
 - vasa previa 366
- Doppler velocimetry 95, 98–99, 101
 - multiple pregnancy 311
- Down syndrome 72–77
 - likelihood ratios 75
 - minor markers 75
 - risk 75
 - screening 310
 - combined first and second trimester 76–77
 - maternal serum 310
 - second trimester 75–76
- drug safety categories 39–41
- Duchenne muscular dystrophy 62
- ductus venosus Doppler waveform analysis 72–73, 291, 292
- duodenal atresia 75
- dysgenic growth restriction 7
- dyspnea of pregnancy 194

- Ebstein anomaly 152–153
- echocardiography
 - fetal 146
 - pregnancy 144
- eclampsia 277–278
 - factor V Leiden mutation 125
 - intrapartum acute myocardial infarction 155
 - management 277–278
 - multiple pregnancy 308–309
- efavirenz 247–248
- Eisenmenger syndrome, maternal 152, 172
- electrocardiography (ECG)
 - cardiac arrhythmias 156
 - maternal 156
 - pregnancy 144
 - pulmonary embolism 137
- emergency care 280–284
- enalapril 42–43
- encephalocele 67
 - alpha-fetoprotein maternal screening 68–69
- encephalopathy
 - hypoxic ischemic 391–392, 394, 452
 - induced cooling 444
- neonatal 375, 452–456
 - antecedents 453
 - brain imaging 455
 - task force 454–455
- end-diastolic flow 99
- endocrinopathies, spontaneous abortion 254–255
- endometritis
 - post-cesarean delivery 383
 - preterm premature rupture of the membranes 346
- β-endorphin 84
- end-stage renal disease 168
- energy
 - requirements in pregnancy 12, 14, 15
 - supplementation 14
- enoxaparin 256
- environmental agents 31–35
 - breastmilk 42
 - lead 32–33
 - mercury 33–34
 - types 34
- enzymatic analysis 416
- epidemiologic studies 31
- epidural analgesia 402
 - patient-controlled 402–403
- epidural anesthesia
 - asthma 198
 - trial of labor 393
- epidural catheterization 402
- epilepsy 201–207
 - delivery 205–206
 - fetal death 203
 - labor 205–206
 - neurodevelopmental outcome 203
 - obstetric complications 205
 - perinatal death 203–204
 - postpartum care 206
 - prenatal screening 203
- erythema infectiosum 222
- erythroblastosis fetalis 320
- erythromycin 234, 235
 - preterm birth 329
 - resistance 234
- estradiol 88
- estriol
 - salivary 336
 - unconjugated 75–76
- estrogens
 - placental production 334
 - teratogenicity 44
- ethical issues, HIV infection 249
- euglycemia
 - maintenance 183
 - pancreas transplantation 171
- exchange transfusion
 - neonatal jaundice 448
 - sickle cell disease 110–111
- exercise, diabetic care 177
- external cephalic version 397
 - failed 427
- extracorporeal membrane oxygenation (ECMO) 447

- factor V Leiden (FVL) mutation 120–121, 126
 - preeclampsia 125
 - spontaneous abortion 255–256
- factor Va 121
- factor VII 133
- factor VIIa, recombinant 283
- factor VIII 143
- factor VIIIa 121
- factor X 133–134
 - activation 283
- factor Xa 121, 133–134
- familial dysautonomia 63, 64
- family history, genetic screening 61
- famine conditions 6, 10
- FDA pregnancy safety category 39–41
- ferritin, serum level 14, 16
- fetal alcohol spectrum disorder 26
- fetal anomalies *see* congenital malformations
- fetal anticonvulsant syndrome 201–203
- fetal dysmaturity syndrome 375
- fetal growth restriction
 - acid–base balance 420
 - cordocentesis 419
 - nutritional 7
 - relative risk of delivery 10
 - symmetric 7
 - transplantation patients 174
- fetal heart rate (FHR)
 - accelerations 104, 105
 - assessment 104, 105
 - baseline 104
 - decelerations 105, 106
 - nonreassuring 105
 - pattern definitions 104–105
 - reassuring 105
 - variability 104–105
- fetal heart rate tracing (FHT) 96
 - interpretation 104–106
- fetal intervention guided by sonography (FIGS) 439–440
- fetal loss *see* abortion, spontaneous
- fetal membranes
 - resealing 350–351
 - see also* preterm premature rupture of the membranes (PPROM)
- fetomaternal hemorrhage 422, 444
- fetomaternal transfusion 410
- fetoscopic surgery (FETENDO) 437–439
 - congenital diaphragmatic hernia 437, 438–439
 - indications 438–439
 - percutaneous 437–438
 - twin–twin transfusion syndrome 437, 438, 439
 - urinary tract obstruction 437, 439
- fetus
 - alcohol abuse effects 24, 25, 26
 - antenatal surveillance 376
 - antepartum monitoring 95–102, 377
 - diagnostic conditions 100–101
 - tests 95–99
 - blood sampling 419–423
 - blood typing through DNA analysis 300
 - bradycardia 422
 - calcium levels 16
 - comprehensive evaluation of condition 3, 4
 - congenital heart block 217
 - cytomegalovirus 230

- fetus (*cont.*)
- death in vasa previa 365–366, 367
 - distress and cesarean delivery 385
 - Doppler imaging 289–293
 - hemorrhage 444
 - prevention 367
 - hyperthermia 443
 - hypoxic brain injury with uterine rupture 391–392
 - infections 222, 223, 224, 227, 230, 231
 - diagnosis 419
 - liver maturity 301
 - malpresentation 385–386
 - maturation 350, 355–356
 - micturition 317
 - movement 95–96, 179, 212
 - oxygen deprivation 290, 291
 - parvovirus infection 222, 223
 - placenta previa complications 364
 - radiation exposure risk 139–140
 - resuscitation 105–106
 - rubella infection 224
 - substance abuse effects 24, 25, 26
 - surgery 433–440
 - surveillance in SLE 218
 - swallowing 317, 318
 - thermoregulation 443
 - toxoplasmosis 227
 - urine 317
 - varicella infection 231
 - weight
 - estimation 287
 - mild preeclampsia 273
 - see also* gestational age; growth, fetal;
 - intrauterine fetal death (IUID);
 - intrauterine growth restriction (IUGR); multiple pregnancy
- fibrillin, defective 153
- fibrinogen 119, 135, 143, 144
- fibrinolysis 134
- fibrinolytic system 119
- fibronectin, fetal (fFN) 336, 337–338
 - prematurity
 - assessment 355
 - evaluation 354
 - preterm premature rupture of the membranes 345
 - prolonged pregnancy 377
- fifth disease 222
- fish consumption 34–35
 - mercury 33–34
- fluconazole 46
- fluoride toxicity 18
- fluoxetine 48–49
- foam stability index (FSI) 92
- folate antagonists 17
- folate/folic acid 17–18
 - fetal karyotype 254
- folic acid supplements 12, 13, 14, 15, 17–18
 - diabetic patients 182
 - prenatal 21
- follicular stimulating hormone (FSH) 83–84, 88
- fondaparinux 129
- formula milks 449–450
- foster care placement 29
- fresh frozen plasma (FFP) 282–283
- functional outcome prediction 70
- fusion inhibitors 247
- galactosemia 450
- genes 61–62
- genetic counseling, multiple pregnancy 309–310
- genetic factors 374–376
- genetic screening 61–65
 - newborn 65
 - prenatal diagnosis 64
 - sickle cell disease 111
- genetic testing 409–417
 - see also* amniocentesis; chorionic villus sampling
- genetics 3, 4
- genital herpes 51
- genital tract cancer, immunosuppressive drugs 168
- German measles 224
- germline mosaicism 61–62
- gestational age 286–287
 - accurate assessment 376
 - criteria for confirmation 374
 - dating error 373
 - inaccuracy 10
 - placenta previa 364
 - prolonged pregnancy 377–378
 - repeat tendency 8
- glomerular filtration rate (GFR)
 - early gestation 38
 - kidney transplantation 170
 - pregnancy 163
- glucocorticoids
 - systemic lupus erythematosus 218, 219
 - thrombocytopenia 114
- glucose
 - blood level determination 183
 - fetal levels 88
 - maternal levels 177–178
- glucose challenge test 176, 180
- glucose tolerance testing (GTT) 176–177
 - gestational diabetes 179, 180
 - pancreas transplantation 171
- glyburide, gestational diabetes 178
- glycemic control, maternal 183–184
- goiter, fetal 87, 89
- gonadotropin releasing hormone (GnRH) 81, 82
 - congenital deficiency 84
- gonadotropins 83–84
- gonads, development 88
- gonorrhea screening 29
- GPIIB/IIIa receptors 133
- Graves' disease 45, 87–88, 89, 188
 - follow-up 189
- growth, fetal 6–9
 - curves 7
 - discordance in multiple pregnancy 306
 - evaluation 287
 - factors affecting 8
 - linear 6–7
 - velocity 7
 - see also* fetal growth restriction
- growth hormone (GH) 84–85
- growth hormone releasing hormone (GHRH) 81, 82, 85
- Haemophilus influenzae* type B vaccination 110
- Hashimoto thyroiditis 87–88, 186
- head circumference:abdominal circumference ratio 7
- hearing loss, solvent abuse 34
- heart, fetal *see* fetal heart rate (FHR); fetal heart rate tracing (FHT)
- heart block, congenital
 - fetal 217
 - neonatal lupus erythematosus 217, 220
- heart disease, congenital 172
 - antiepileptic drug exposure 202
- heart rate, fetal
 - IUGR 293
 - sinusoidal tracing 366
 - vasa previa 366
- heart rate, maternal 144
- heart transplantation 172
 - pregnancy after 156, 158
- heart valve disease, maternal 146–151
 - fetal/maternal risk 148
- heart valves, mechanical 149–151
- HELLP syndrome 171, 173, 275–277
 - dexamethasone 48
 - diagnostic criteria 275
 - factor V Leiden mutation 125
 - management 276–277
 - multiple pregnancy 308, 312–313
 - platelet transfusion 282
 - SLE differential diagnosis 216
 - thrombocytopenia 114
- hemoglobin 14, 15, 16, 109
 - glycosylated 182, 184
- hemoglobin S 109
- hemoglobin S/beta-thalassemia disease 110
- hemoglobin SC disease 109–110
- hemoglobin SS disease 109
- hemoglobinopathies 109–110
 - carrier screening 62, 63–64
 - see also* sickle cell disease
- hemolysis, elevated liver enzymes and low platelet count syndrome *see* HELLP syndrome
- hemolytic disease of the newborn 298–301, 302, 445
 - end-stage phase 299
 - jaundice 448
 - non-RhD antibodies 301–302
- hemophilias, recombinant factor VIIa 283
- hemorrhage
 - fetal 367, 444
 - fetomaternal 422, 444
 - neonates 444–445
 - see also* blood loss; intracranial hemorrhage
- hemostasis
 - physiology 133–134
 - pregnancy changes 119, 120, 135
- heparin 134
 - disseminated intravascular coagulation 281–282
 - systemic lupus erythematosus 219, 220
 - thrombocytopenia 128–129

- heparin, low-molecular weight 128, 129
 mechanical heart valve anticoagulation 149–150
 systemic lupus erythematosus 219
 thrombophilia 126–127
 heparin, unfractionated 128, 129
 mechanical heart valve anticoagulation 149, 150, 151
 systemic lupus erythematosus 219
 heparin cofactor II 134
 heparinization, systemic in neonates 447
 hepatic disease
 acute fatty liver of pregnancy 309
 liver transplantation 171–172
 hepatitis
 perinatal infection 238–240
 hepatitis A 238
 hepatitis B 239
 chronic carrier state 239
 hepatitis D coinfection/superinfection 239
 screening 29
 transplantation patients 169
 vaccination 110
 hepatitis C 239–240
 liver transplantation 171
 screening 29
 transplantation patients 169
 hepatitis D 239
 hepatitis E 238
 hepatitis G 240
 herpes, genital 51
 herpes simplex virus 227–229
 clinical manifestations 228
 diagnosis 228
 management 228–229
 pathogenesis 227–228
 preterm premature rupture of the membranes 350
 transmission 227–228
 transplantation patients 169
 highly active retroviral therapy (HAART) 243, 247–248, 249
 homocysteine 123
 hormones
 fetal hypothalamus 81–83
 fetal pituitary 83–85
 placental 7
 teratogenic 44
 hospital care for substance abuse 29–30
 human chorionic gonadotrophin (hCG)
 Down syndrome 76, 310
 first trimester screening 74
 hypothyroidism 186–187
 maternal blood determination 420–421
 placental 88
 human immunodeficiency virus (HIV) 242–249
 antiretroviral drugs 243, 244–247, 247–248
 breastfeeding contraindication 450
 counseling 243
 ethical issues 249
 infected patient identification 242–243
 legal issues 249
 mother-to-child transmission
 prevention 243
 preterm premature rupture of the membranes 350
 screening 29
 seropositive women 243, 247–248
 testing 242–243
 transplantation patients 169
 human papillomavirus (HPV) 169
 human platelet antigens (HPAs) 115, 117
 hydralazine 50, 211, 212
 eclampsia management 278
 hydration, preterm labor 356
 hydrocephalus 69
 open fetal surgery 436
 hydrops fetalis 75
 parvovirus infection 222, 223
 hydroxychloroquine 218
 1,25-hydroxycholecalciferol 17
 21-hydroxylase deficiency 86, 89
 17 α -hydroxyprogesterone caproate (17-OHPC) 311, 329, 330, 331
 hyperglycemia
 fetal 183
 first trimester 17
 maternal 183
 hyperhomocysteinemia 123
 hypernatremic dehydration 450
 hypertension, maternal 165–166
 chronic 210–213
 classification 210
 delivery indications 212–213
 differential diagnosis 210, 211
 evaluation 210–211
 fetal evaluation 212
 gestational 271–279, 308–309
 heart transplantation 172
 kidney transplantation 170–171, 173
 medications 50
 teratogenicity 42–43
 mild 272–273
 multiple pregnancy 308–309
 postpartum follow-up 213
 preconceptional therapy guidelines 210
 severe 279
 therapy during pregnancy 211–212
 see also eclampsia; preeclampsia
 hyperthermia, fetal 443
 hyperthyroidism
 fetal 88
 maternal 188–189
 hypoglycemic agents, gestational diabetes 178
 hypotension, maternal 404
 hypothalamic–pituitary–adrenal (HPA) axis 82
 premature activation 333–334
 hypothalamus, fetal
 hormones 81–83
 ontogeny 81
 hypothyroidism
 fetal 87–88
 neonatal 448
 hypothyroidism, maternal 186–190
 diagnosis 186–187
 follow-up 188
 treatment 187–188
 hypoxia ischemia, intrapartum 455
 hysterectomy
 placenta accreta 368
 repeat cesarean delivery 384
 uterine rupture 391, 392, 394
 hysterotomy 433–437
 closure 383
 indications 436–437
 postoperative recovery 435–436
 risks and benefits 433–434
 technique 434–436
 ibuprofen 49–50
 idiopathic thrombocytopenic purpura (ITP) 113–114
 immigrant women, preterm births 327
 immunoglobulin A (IgA) 449
 immunoglobulin E (IgE) 193
 immunosuppressive drugs 156, 158
 fetal circulation 174
 genital tract cancer 168
 pregnancy 169–170
 indomethacin 198
 polyhydramnios 321
 preterm labor 357–358, 359
 infections
 asthma effects 193
 congenital 419
 cordocentesis 422
 fetal 222, 223, 224, 227, 230, 231
 diagnosis 419
 intra-amniotic 354
 perinatal 222–232
 streptococci group B 234–236
 prematurity management 354
 preterm birth 329, 334
 preterm premature rupture of the membranes 345, 347, 350
 spontaneous abortion 254
 transplantation patients 169
 see also named infections
 inferior vena cava, Doppler waveform 291, 292, 293
 inflammatory pathway markers 336
 inhalers, optimum technique 196
 inhibin 88
 inhibin-A serum levels 76
 insulin
 administration 183
 fetal levels 88
 gestational diabetes 178
 resistance 176, 179
 insulin-like growth factor I (IGF-I) 85, 89
 insulin-like growth factor II (IGF-II) 89
 interleukin 6 (IL-6) 336
 interleukin 8 (IL-8) 336
 internal iliac artery embolization 368
 interpregnancy interval 392
 intracranial aneurysm rupture 151
 intracranial hemorrhage
 extracorporeal membrane oxygenation 447
 fetal thrombocytopenia 114–115, 116
 intrapartum event criteria 454
 intrapartum hypoxia ischemia 455
 intrauterine fetal death (IUFD) 95
 multiple gestation 306–307, 308
 single in twin pregnancy 304

- intrauterine growth restriction (IUGR)
 99, 287–294
 asymmetric 287
 definition 287
 Doppler imaging 289–293
 genetic syndromes 289
 inherited thrombophilia 125
 management 288–293
 maternal hypertension 212
 multiple pregnancy 306, 308
 neonatal encephalopathy 454
 oligohydramnios 322
 outcome 288
 risk factors 288
 symmetric 287
 systemic lupus erythematosus 217
- intravenous immunoglobulin (IVIG)
 spontaneous abortion prevention 257
 thrombocytopenia 114, 115, 116
- iodine
 deficiency 19, 87
 endemic 186
 toxicity 18
- iron 15
 supplementation 14–16
 toxicity 18
- iron fumarate 15
 iron gluconate 15
 iron sulfate 15
 isotretinoin 47
- jaundice
 neonatal 447–448, 449
 treatment 448
- Jewish genetic diseases 62, 64, 65
 jugular vessel ligation 447
- Kallmann syndrome 83–84
 karyotype analysis 69–70
 cordocentesis 419
 oligohydramnios 322, 427
- Kell antibody 301, 302
 kernicterus 447–448
 kick counts 95–96
 gestational diabetes 179
 maternal hypertension 212
- kidney
 fetal bilateral cystic dysplasia 322
 maternal transplantation 168–171
 graft function 170
 obstetric emergencies 173
 pancreas combination 172
 rejection 170
see also renal entries
- labetalol 50
 eclampsia management 278
 renal insufficiency 166
- labor
 analgesia/anesthesia 401–403
 asthma management 198
 augmentation 393
 breech delivery 399
 labor arrest 385
 epilepsy 205–206
 failure to progress 385
 induction
 eclampsia 278
 post-term 377
 uterine rupture 393
 oligohydramnios 427, 428
 prophylactic amnioinfusion 427, 428
 sickle cell disease 111
 status 391
 trial of 389–395
 labor, preterm 354
 delivery 359
 diagnosis 354–355
 interventions 355–359
 neonatal morbidity/mortality
 prevention 355–356
 tocolytic therapy 356–359
 transplantation patients 173
see also preterm delivery; preterm
 premature rupture of the
 membranes (PPROM)
- lactation 449–450
 benefits 18–19
 bone turnover 16
 dietary recommendations 19–20
 iron requirements 15
see also breastfeeding; breastmilk
- lactotrophs 85
 lamellar body counts 92, 93
 lamotrigine
 clearance during pregnancy 205
 congenital malformations 202, 203
 monotherapy 207
- laparotomy, fetal intervention guided by
 sonography 440
- lead toxicity 32–33
 lecithin:sphingomyelin (L:S) ratio 91, 93
 left ventricular failure 281
 left ventricular filling maintenance
 147–148
 left ventricular function 154
 leukotriene receptor antagonists 197
 levothyroxine 188, 189, 190
 limb reduction defects 414–415
 lisinopril teratogenicity 42–43
 lithium 46
- liver
 acute fatty liver of pregnancy 309
 transplantation 171–172
- long-chain polyunsaturated (LCP) fatty
 acids 449
- low birthweight
 asthma association 193
 heart transplantation 172
 multiple pregnancy 304
 neonatal deaths 442
- lung, fetal
 fluid 317–318
 maturity 91–93, 354
 profile 92
see also surfactant
- lung transplantation, maternal 172–173
 lupus anticoagulant 123–124, 214, 217,
 218–219
 spontaneous abortion 256–257
- lupus erythematosus
 neonatal 217
see also systemic lupus erythematosus
 (SLE)
- lupus flares 214–216
 diagnosis 218
- lupus nephropathy 216–217
 luteinizing hormone (LH) 83–84, 88
- McDonald cerclage 264–265, 266
 α_2 -macroglobulin 134
 macrosomia
 diabetes mellitus 184
 gestational diabetes 179
 post-term infants 375
- magnesium
 deficiency 19
 requirements in pregnancy 12, 14, 15,
 16–17
 toxicity 18
- magnesium sulfate 102, 105, 279
 asthma 198
 eclampsia management 277–278
 preterm labor 358
 severe preeclampsia 273
- magnetic resonance angiography (MRA)
 138
- magnetic resonance imaging (MRI)
 DVT 136
 placenta accreta diagnosis 368
 malpresentation, fetal 385–386
see also breech presentation
- Marfan syndrome, maternal 153
- maternal age
 dizygotic twins 309
 genetic counseling 309–310
 trial of labor 390
- maternal serum alpha-fetoprotein
 (MSAFP) screening 67–69, 70, 71
 combined first/second trimester 76
 multiple pregnancy 310
 placenta accreta diagnosis 368
 second trimester 75–76
- matrix metalloproteinases 334–335
 measles–mumps–rubella (MMR) vaccine
 224
- meconium
 lamellar body count 92
 thick 429
- meconium aspiration syndrome 375,
 428–429, 430
- meconium-stained amniotic fluid
 428–429, 430
- medications 38–52
 asthma 196–198
 breastfeeding 42–43, 48, 49, 50, 51, 52
 teratogens 42–43, 44, 45, 46, 47
 clearance 38, 39
 paternal exposure 39
 pharmacokinetics 38, 39
 systemic lupus erythematosus 218
- medroxyprogesterone acetate 44
 meiotic rescue 416
- mendelian disorders 61–65
 mendelian inheritance 61–62
- meningocele 67
see also myelomeningocele
- menstrual data
 inaccuracy 10
 unreliable 6
- mercury 33–34
 metabolic acidosis
 intrapartum hypoxia ischemia 455
 respiratory distress syndrome 446

- methimazole 188–189
methimazole–carbimazole 45
methotrexate 44–45, 368
 contraindication in pregnancy 218
methyl mercury 33
methyldopa 50
 renal insufficiency 166
methylene tetrahydrofolate reductase (MTHFR), thermolabile mutant gene mutation 123
methyltestosterone 44
metronidazole 51
microcephaly
 antiepileptic drugs 203
 fetal swallowing 318
micturition, fetal 317
middle cerebral artery (MCA)
 Doppler evaluation 223, 290–291, 299–300
 IUGR fetuses 99, 290–291
milk, vitamin D-fortified 17
minerals, toxicity 18
miscarriage see abortion, spontaneous
misoprostol 46–47
mitral regurgitation 148
mitral stenosis
 left ventricular filling maintenance 147–148
 maternal 146–148
mitral valve prolapse, maternal 148–149
mitral valvuloplasty, percutaneous balloon 146
molybdenum toxicity 18
monoamniocity 305, 307–308
monochorionicity 304, 305
 fetal complications 307–308
monozygotic pregnancy 305
mosaic morula 416
mosaicism
 confined 415–416
 cordocentesis 419
 mucous patches 225
müllerian duct anomalies 255
multifetal pregnancy reduction (MPR) 307, 309
multiple pregnancy 304–313
 amniocentesis 410, 411
 anatomic abnormalities 310
 aneuploidy 310
 antenatal surveillance 311
 antepartum management 309–312
 counseling 307
 discordant anatomic abnormalities 307
 fetal complications 306–307
 fetal lung maturity 93
 fetal wastage 306–307
 genetic counseling 309–310
 HELLP syndrome 308, 312–313
 intrapartum monitoring 311–312
 maternal nutrition 11
 neural tube defects 310
 oligohydramnios 323
 perinatal outcomes 304–305
 polyhydramnios 323
 post-term definition 378
 prenatal diagnosis 309–310
 preterm delivery prevention 310–311
 ultrasound 311, 312
 uterine mechanical stretching 335
multivitamins, prenatal 12, 13, 14, 15
mycophenolate mofetil 156, 158
mycoplasma 254
myelomeningocele 67
 functional outcome 70
 open fetal surgery 436–437
 see also neural tube defects
myocardial infarction (MI), acute
 maternal 155–156
myoma, submucous uterine 255
nasal bone sonography 72
natural killer (NK) cells 257
necrotizing enterocolitis 355
neonatal alloimmune thrombocytopenia (NAIT) 115, 116–117
neonatal lupus erythematosus 217
neonates
 anemia 444–445
 cytomegalovirus 229, 230
 deaths 442
 encephalopathy 452, 453–456
 extracorporeal membrane oxygenation 447
 genetic screening 65
 hemorrhage 444–445
 hepatitis B infection 239
 herpes simplex virus infection 228
 hypothermia 443
 jaundice 447–448, 449
 morbidity / mortality prevention in preterm labor 355–356
 respiratory disorders 445–447
 thermal regulation 443
 varicella infection 231
nephrotic syndrome, pregnancy 164–165
neural tube defects 17, 18
 antiepileptic drug exposure 202
 diagnostic ultrasound 69–70
 folic acid supplements 182
 multiple pregnancy 310
 open fetal surgery 436–437
 prognosis 70
 screening 67–71
 serum screening 67–69
 see also myelomeningocele
neurohypophyseal hormones 83
neutrophils, decidual 335
nevirapine 248
New York Heart Association (NYHA)
 cardiac disease classification 143–145
nicardipine 357
nifedipine 211, 212
 eclampsia 278
 preeclampsia post-partum management 275
 preterm labor 357
nipple stimulation 98
Nitrazine 354
non-steroidal anti-inflammatory drugs (NSAIDs) 50
 after cesarean delivery 404
 teratogenicity 41
non-stress test (NST) 95, 96–97, 99, 101
 maternal diabetes 184
 maternal hypertension 212
 mild preeclampsia 273
 prolonged pregnancy 376
nuchal translucency (NT)
 Down syndrome 310
 sonography 72, 73, 76, 77
nutrition, maternal 6–21
 assessment 11–12, 13, 14, 15
 dietary recommendations 19–20
 gestational diabetes 177
 interventions 12–18
obesity 11
 failure to progress in labor 385
 trial of labor 390
 weight gain target levels 20
obstetric complications
 antiphospholipid antibodies 124–125
 epilepsy 205
 inherited thrombophilia 125–126
 multiple pregnancy 308–309
 systemic lupus erythematosus 217
obstetric emergencies, transplantation patients 173–174
oligohydramnios 321–323
 amnioinfusion 322, 323, 425, 426, 427, 428, 431
 clinical significance 322–323
 congenital anomalies 427
 definition 319, 321
 diagnosis 321–322
 fetal swallowing 318
 fetal urinary system malformations 317
 IUGR fetus 322
 labor prophylaxis 427, 428
 membrane rupture 346
 multiple pregnancy 305–306, 323
 postdate pregnancy 322–323, 375, 377
 preterm premature rupture of the membranes 350
 twin pregnancy 323
 ultrasound 321–322
 variable decelerations 426
omega-3 LCP fatty acids 449
omega-6 LCP fatty acids 449
oocytes 253
opioids
 intrathecal 402
 regional analgesia 401
orange juice, iron absorption 15
organ systems, pregnancy effects 38, 39
organic solvents 34
oxygen deprivation, fetal adaptation 290, 291
oxygenation, fetal markers 105
oxygen-carrying capacity, respiratory distress syndrome 446
oxytocin 83
 labor augmentation 393
 breech delivery 399
 for labor arrest 385
 uterine contractions 98
oxytocin challenge test 376
oxytocin receptor 334
oxytocin receptor antagonists 359

- pancreas transplantation 171,172
 pancreatic hormones 88–89
 parathyroid hormone (PTH) 16
 parvovirus B₁₉ 222–224
 patent ductus arteriosus, maternal 152
 patient education, asthma 195–196
 patient-controlled analgesia (PCA), intravenous 404
 patient-controlled epidural analgesia (PCEA) 402–403,404
 penicillamine 47
 penicillin 234,235
 resistance 234
 penicillin G 51,226
 percutaneous balloon mitral valvuloplasty 146
 perinatal medicine, advances 3,4
 perinatal mortality
 asthma association 193
 epilepsy 203–204
 underweight women 9–10
 uterine rupture 391
 persistent pulmonary hypertension of the newborn (PPHN) 49
 pesticides 34
 phenobarbital 202,301
 phenytoin, teratogenicity 43
 phosphatidylglycerol assessment 91–92, 93
 phototherapy, neonatal jaundice 448
 pituitary, fetal
 anterior 83–85
 ontogeny 81
 placenta
 absorptive capacity 7
 confined mosaicism 415–416
 disorders 362–369
 environmental agents 32
 famine conditions 10
 hormone production 7
 malformation 444
 manual removal 383
 migration 363–364
 preferential growth 364
 separation failure 367–368
 teratogenic drugs 39
 see also abruptio placentae
 placenta accreta 367–368
 repeat cesarean delivery 384
 placenta previa 362–365
 clinical presentation 362
 complications 364
 delivery timing 365
 diagnosis 362–363
 fetal hemorrhage 444
 incidence 362
 management 364
 repeat cesarean delivery 384
 risk factors 362
 types 363
 placental hormones 7
 placental sulfatase deficiency 373
 plasma products transfusion 282–283
 plasma volume 143,144
 plasminogen activator inhibitor 1 (PAI-1) 119,134
 elevated levels 122–123,135
 plasminogen activator inhibitor 2 (PAI-2) 119,134
 elevated levels 135
 platelet aggregation 133
 platelet count
 fetal 115–116
 HELLP syndrome 277
 thrombocytopenia 114,116
 platelet plug formation 133
 platelet transfusions 282
 thrombocytopenia 114,116
 pneumonia
 sickle cell disease 110
 varicella 231
 polychlorinated biphenyls (PCBs) 34
 polycystic ovarian syndrome (PCOS) 254
 polyhydramnios 319–321
 associations 320–321
 fetal swallowing 318
 fetal urinary system malformations 317
 management 321
 multiple pregnancy 323
 uterine mechanical stretching 335
 polyploidy, spontaneous abortion 253
 polyyps, uterine 255
 ponderal index 7
 postdate pregnancy *see* prolonged pregnancy
 postpartum care, alcohol/substance abuse 29–30
 Prader–Willi syndrome 416
 prednisone 170
 thrombocytopenia 114
 preeclampsia 271–275
 asthma association 193
 birth weight 7
 etiology 272
 factor V Leiden mutation 125
 heart transplantation 172
 hypertension 212–213
 inherited thrombophilia 125
 intrapartum acute myocardial infarction 155
 kidney transplantation 170–171
 management 272,274–275
 mild 272–273,274
 multiple pregnancy 308–309
 pathophysiology 272
 postpartum management 275
 prediction 278–279
 prevention 278–279
 renal disease 211
 severe 273–275,279
 systemic lupus erythematosus 217
 thrombocytopenia 114
 transplantation patients 173
 pregnancy, immunosuppressive drugs 169–170
 Pregnancy Nutrition Surveillance System 20
 pregnancy-associated plasma protein A (PAPP-A) 73–74,76
 Down syndrome 310
 prematurity
 assessment 354–355
 asthma association 193
 evaluation 354
 extreme 442
 heart transplantation 172
 interventions 355–359
 management 354–360
 neurodevelopmental sequelae 450
 outcomes 442–443
 prognosis 442
 risk factors 443
 survival 442
 syphilis 225
 transplantation patients 174
 see also labor, preterm; preterm delivery; preterm premature rupture of the membranes (PPROM)
 prenatal diagnosis, genetic disease 64
 preterm delivery
 abruption-associated 335
 bacterial vaginosis 334
 cervical cerclage 328–329
 decidual-amnion-chorion inflammation 334–335
 diagnostic accuracy 337–338
 etiology 333–335
 financial costs 326
 handicap risk 326
 infections 329,334
 maternal body mass index 10
 maternal weight 10
 multiple pregnancy 304,310–311
 pathway-specific markers 336–337
 prediction 335–337
 prevention 326–331
 multiple pregnancy 310–311
 progesterone prophylaxis 329–331
 recurrent 331
 social phenomenon 326–327
 spontaneous 263
 see also labor, preterm
 preterm premature rupture of the membranes (PPROM) 345–351
 abruption-associated 335
 cerclage management 267
 cervical cerclage 350
 cervical incompetence 267,268
 counseling 349–350
 deceleration prevention 427–428
 fetal membrane resealing 350–351
 infections 345,347,350
 management 347–350
 mechanisms 345
 oligohydramnios 322
 prediction 345–346
 prematurity management 354
 prevention 326,345–346
 previable 349–350
 progesterone in prevention 330
 streptococci group B 235,236
 systemic lupus erythematosus 217
 transplantation patients 173
 progesterone
 prophylaxis for preterm birth 329–331
 spontaneous abortion 254–255
 progestogens, preterm birth prevention 329–331
 prolactin 85
 spontaneous abortion 255

- prolonged pregnancy 373–379
 antenatal fetal surveillance 376, 377
 cesarean delivery 377
 definition 373
 delivery timing 376–378
 etiology 373–374
 genetic factors 373–374
 incidence 373
 intrapartum management 378
 management 376–378
 maternal risk 375–376
 multiple pregnancy 378
 oligohydramnios 322–323
 prevention 376–378
 prognosis 378
 stillbirth 374, 375, 377
- proopiomelanocortin (POMC) 84
- propoxyphene 49–50
- propranolol 50
- propylthiouracil (PTU) 87, 88, 89
- hyperthyroidism 188
- thyroid storm 189
- prostaglandins
- corticotropin-releasing hormone effects 333–334
- delivery 198
- final common pathway of delivery 335
- protease inhibitors (PIs) 243, 245–247
- protein, dietary supplementation 14
- protein C deficiency 121
- protein S 121, 134
- deficiency 121, 126
- pregnancy 119, 135
- protein Z deficiency 122, 134
- proteinuria, maternal 164–165, 165
- hypertension 211, 213
- prothrombin gene G20210A mutation 121, 125, 126
- psychiatric disorders, substance abuse 26–27
- pulmonary angiography
- fetal risk 139–140
- pulmonary embolism 138
- pulmonary arteriography 137
- pulmonary artery pressure 152
- pulmonary edema 158
- aortic stenosis 149
- lung transplantation 173
- pulmonary embolism 133, 136–140
- D-dimer assays 137–138
- diagnostic algorithm 139
- diagnostic studies 137
- patient work-up 139
- risk assessment 136, 137
- pulmonary hypertension, persistent of the newborn (PPHN) 49
- pulmonary hypoplasia
- congenital diaphragmatic hernia 438
- oligohydramnios 322
- pulmonary maturity tests 91–93
- pulmonary valve lesions, maternal 148
- pyelonephritis, sickle cell disease 110
- rachischisis defect 67
- radiation exposure, fetal risk 139–140
- radiiodine therapy, ablative 186
- red blood cells
- defects 445
- hemolysis 109
- mass in pregnancy 143, 144
- packed 282
- prophylactic transfusion 110–111
- transfusion 282, 301
- reflux, asthma exacerbation 194, 195
- renal agenesis 317
- renal blood flow 163
- renal disease, maternal 163, 164–167
- hypertension 211
- lupus nephropathy 216–217
- nephrotic syndrome 164–165
- renal failure
- chronic 168
- multiple pregnancy 308
- renal insufficiency, maternal 165–166
- renal tubular function, maternal 164
- respiratory distress syndrome 91, 445–446
- gestational diabetes 179
- risk 92–93
- surfactant therapy 446
- resuscitation, fetal 105–106
- retinoids 47
- retinol 18
- rhesus alloimmunization 3, 298–301, 302, 448
- antibody titers 299
- clinical management 300
- fetal blood typing 300
- fetal lung maturation delay 93
- intrauterine transfusion 300–301
- prophylaxis 298, 299
- surveillance 299–300
- thrombocytopenia 114
- rhesus antigen (RhD) 298
- rhesus immunoglobulin (RhIg) 298, 299, 448
- amniocentesis 410
- rhesus sensitization, transplantation
- patients 169
- rhesus status, blood product replacement 282, 283
- rheumatic heart disease 146, 149
- ritodrine 105, 356–357
- rubella 224
- sacrococcygeal teratoma 433, 437
- scalp stimulation 105
- seizures
- control 206
- during delivery 205–206
- eclampsia 277, 278
- during pregnancy 204
- selective serotonin reuptake inhibitors (SSRIs) 48–49
- selective termination (ST) 307, 308
- selenium toxicity 18
- serine protease inhibitors (SERPINs) 134
- sertraline 48–49
- sexually transmitted infections
- premature rupture of the membranes 345, 347
- premataturity management 354
- Sheehan syndrome 186
- Shirodkar cerclage 264
- shock
- cardiogenic with amniotic fluid embolism 280
- neonates 444, 445
- shoulder dystocia, gestational diabetes 179
- sickle cell crisis 109, 110
- sickle cell disease 63–64, 109–112
- fetal assessment 111
- genetic evaluation 111
- red blood cell prophylactic transfusion 110–111
- sickle hemoglobin (S) *see* hemoglobin S
- sinusitis, asthma exacerbation 194–195
- sirolimus 170
- small for gestational age 287
- see also* intrauterine growth restriction (IUGR)
- smoking 27
- sodium retention in pregnancy 163
- solvent abuse 34
- somatostatin 81, 82
- sonography *see* ultrasound
- sphingomyelin 91
- spina bifida
- antiepileptic drug exposure 202
- open 67
- alpha-fetoprotein maternal screening 68–69
- ultrasonography 69
- outcome 70
- screening 71
- see also* neural tube defect and myelomeningocele
- spinal analgesia 402
- spinal anesthesia 404
- spiramycin 227
- splenectomy, thrombocytopenia 114, 115
- steroidogenesis 88
- steroids 47–48
- see also* corticosteroids
- stillbirth
- epilepsy 203
- post-term pregnancy 374, 375, 377
- syphilis 225
- systemic lupus erythematosus 217
- streptococci group B (GBS) 234–235, 236
- antibiotics 234, 235
- epidemiology 234
- isolation 234
- premataturity management 354
- preterm labor 356
- prevention 235, 236
- stress
- fetal
- markers 336–337
- preterm delivery 333–334
- maternal 6
- preterm delivery 333–334
- stroke volume 284
- pregnancy 144
- stuck twin 305–306
- substance abuse 24–30
- fetal effects 24, 25, 26
- hospital care 29–30
- postpartum care 29–30
- pregnancy management 26–27
- prenatal care 27, 28–29, 29

- substance abuse (*cont.*)
 screening 24
 withdrawal 27
 sulindac 359
 surfactant
 fetal lung 91–92
 neonatal therapy 3, 4
 therapy 446
 surfactant:albumin ratio 92
 surgery, fetal 433–440
 endoscopic 437–439
 open 433–437
 sonography-guided 439–440
 swallowing, fetal 317, 318
 syphilis 225–226
 screening 29
 systemic lupus erythematosus (SLE)
 123–124, 211, 214–220
 diagnostic criteria 214, 215
 differential diagnosis 216
 drug regimens 218
 epidemiology 214
 etiology 214
 fetal surveillance 218
 management 217–218
 morbidity/mortality 216
 pathogenesis 214–216
 pregnancy effects 216–217

 tachycardia prevention 147, 148
 tachypnea, transient 446–447
 tacrolimus 156, 170
 Tay–Sachs disease 63, 64
 teratogenicity evaluation 41–42
 teratogens 38–42
 FDA pregnancy safety category
 39–41
 follow-up studies 41
 identification 41–42
 immunosuppressive drugs 169–170
 known 41, 42–47
 neural tube defects 17
 time of exposure 38
 terbutaline 105, 356–357
 testes, fetal 88
 testosterone 88
 tetracyclines 51
 tetralogy of Fallot, maternal 153
 thalassemias 63, 64
 hemoglobin S/beta-thalassemia disease
 110
 thalidomide
 neural tube defects 17
 teratogenicity 41, 47
 theophylline 197
 thimerosal 33
 thrombin 134, 335
 thrombin-activatable fibrinolysis
 inhibitor (TAFI) 134
 thrombin–antithrombin (TAT) complexes
 336–337
 thrombocytopenia 113–117
 alloimmune 115–116
 neonatal 115, 116–117
 autoimmune 113–115
 fetal 114–116, 420
 gestational 113, 116
 heparin-induced 128–129
 maternal 113–114
 platelet transfusion 282
 thromboembolic disorders 133–140
 diagnosis 135–140
 pathophysiology 135
 pregnancy 143
 risk factors 135
 thrombophilia
 acquired 123–125
 adverse pregnancy outcome prevention
 126–127
 inherited 119–123, 125–126
 recurrent miscarriage 255–256
 management 127, 128
 pregnancy 143
 prevention 127
 screening 127
 thromboprophylaxis, cesarean delivery
 383
 thyroglobulin 87
 thyroid, fetal 86–88
 dysgenesis 87
 thyroid, maternal 87
 thyroid disease, maternal 87, 88
 thyroid stimulating hormone (TSH)
 85
 thyroid stimulating hormone (TSH)
 receptor 87
 thyroid storm 189
 thyroidectomy 186
 thyroiditis
 chronic autoimmune 186
 postpartum 189
 transient immune 189
 thyroperoxidase (TPO) 87
 thyrotoxicosis 188
 thyrotropin-releasing hormone (TRH)
 81, 82, 85
 thyroxine (T₄) 87
 gene mutations 87
 hyperthyroidism diagnosis 188
 hypothyroidism diagnosis 186–187
 intra-amniotic administration 88
 tissue factor 133–134
 decidual 336
 tissue factor pathway inhibitor (TFPI)
 134
 tissue-type plasminogen activator (tPA)
 134
 tocolytic therapy 105
 cervical cerclage 267
 maintenance 359
 multiple pregnancy 311
 preterm birth prevention 327
 preterm labor 356–359
 primary 359
 refractory 359
 toluene 34
 tonic-clonic seizures 204
 labor 205–206
Toxoplasma gondii (toxoplasmosis)
 226–227
 tracheal occlusion 438–439
 transfusion
 blood product replacement
 282–283
 intrauterine 223–224, 300–301, 302
 maternal in placenta previa 364
 neonatal in vasa previa 367
 neonatal jaundice 448
 platelet 114, 116, 282
 red blood cells 282, 301
 sickle cell disease 110–111
 transplantation patients 168–174
 anteartum care 168–169
 follow-up of offspring 174
 intrapartum management 173
 pregnancy timing 168
 prepregnancy assessment/counseling
 168
 urinary tract infections 169
 transposition of the great vessels,
 maternal 153
 trapped twin syndrome 323
Treponema pallidum (syphilis) 225–226
 trial of labor 389–395
 birthweight 390
 candidates 389–390
 cervical examination 391
 counseling 394
 interpregnancy interval 392
 management 393–394
 oxytocin labor augmentation 393
 risks 391–393
 success rate 390–391
 uterine rupture risk 391–393
 tricuspid regurgitation
 heart transplantation 172
 sonographic screening 72
 tricuspid valve lesions, maternal
 148
 tri-iodothyronine (T₃) 87
 trinucleotide repeats 62
 trisomies 253–254
 trisomy 15 416
 trisomy 18 75
 tuberculosis screening 29
 twin pregnancy
 dizygotic 305, 309
 fetal lung maturity 93
 oligohydramnios 323
 stuck twin 305–306
 vanishing twin 306
 zygosity 305
 see also multiple pregnancy
 twin–twin transfusion syndrome 304,
 308, 310
 cordocentesis 420
 fetoscopic surgery 437, 438, 439
 management 323
 oligohydramnios 323
 polyhydramnios 321
 see also stuck twin

 ultrasound
 amniocentesis 409, 411
 cervical incompetence 265–266
 cervical length 338
 chorionicity diagnosis 305–306
 dating of pregnancy 286–287
 fetal anomaly detection 310
 fetal growth evaluation 287
 fetal intervention guiding
 439–440
 fetal weight estimation 273
 fetoscopic surgery 438

- first trimester
 - combined with serum screens 73–74
 - screening 72–73
- gestational age 286–287
- intrauterine growth restriction 289–293
- multiple pregnancy 311, **312**
- neural tube defects diagnosis 69–70
- oligohydramnios 321–322
- placenta accreta diagnosis 367–368
- placenta previa diagnosis 362–363
- prematurity evaluation 354
- rhesus alloimmunization surveillance 299–300
- second trimester
 - routine 69
 - screening 75
- transvaginal 362–363
- vasa previa diagnosis 366
- venous thromboembolism 136, 138–139
 - see also* Doppler imaging
- umbilical artery
 - circulation 290
 - Doppler imaging 290, 291, 292–293
 - end-diastolic flow 99
- umbilical circulation 443
- umbilical cord
 - blood studies 456
 - compression in postdate pregnancy 375, 377
 - cordocentesis 420
 - hematoma 422
 - malformation 444
 - puncture site bleeding 422
- umbilical vein
 - cordocentesis 420
 - red cell intravascular transfusion 301
- underweight women 9–10
 - weight gain target levels 20
- ureaplasma urealyticum 254
- urinary tract infections, transplantation patients 169
- urinary tract obstruction, fetoscopic surgery 437, 439
- urine, fetal 317
- urogenital defects
 - antiepileptic drug exposure 202
 - oligohydramnios 322
- uterine activity
 - eclampsia 278
 - multiple pregnancy 311
- uterine contractions, ambulatory monitoring 311
- uterine rupture
 - hysterectomy 391, 392, 394
 - interpregnancy interval 392
 - labor induction 393
 - risk factors 392–393
- uterus
 - abnormalities 255
 - closure technique 392, 435
 - incisions
 - placenta previa 365
 - previous type 391
 - repair after cesarean delivery 383
 - vasa previa 367
 - mechanical stretching 335
 - rupture risk 391–393
 - surgical entry 434, 435, 436
- vaginal birth after cesarean delivery 383, 389–395
 - counseling 394
 - labor status 391
 - management 393–394
 - multiple prior cesarean deliveries 391
 - oxytocin labor augmentation 393
 - previous incision type 391
 - rate 384
 - risks 391–393
 - success rate 390–391
 - trial of labor 389–395
 - uterine rupture risk 391–393
- vaginal bleeding
 - placenta previa 364
 - vasa previa 365–366
- vaginal delivery
 - analgesia/anesthesia 401–403
 - breech presentation 397–398, 400
 - selection criteria 398–399
 - technique 399
- vaginal pessaries 267–268
- vaginal pool collection 91
- valacyclovir 228–229
- valproic acid
 - neural tube defects 17, 202
 - teratogenicity 43, 203, 207
- vancomycin 234, **235**
- vanishing twin 306
- variable deceleration relief, amnioinfusion 426
- varicella zoster virus 231–232
- varicella-zoster immunoglobulin (VZIG) 232
- vasa previa 365–367
 - diagnosis 366
 - incidence 365
 - management 366–367
 - outcomes 367
 - pathophysiology 365
 - risk factors 365
- vasoconstriction 133
- vaso-occlusion 109
- sickling 110
- vasopressin *see* antidiuretic hormone (ADH)
- venous thromboembolism 133
 - diagnosis 135–140
 - inherited thrombophilia association 120
 - risk 133
 - thrombophilia 123, 124
- venous ultrasonography
 - DVT 136
 - pulmonary embolism 138–139
- ventilation–perfusion (V/Q) scanning
 - fetal risk 139–140
 - pulmonary embolism 138
- ventricular septal defect, maternal 151
- ventriculomegaly, fetal 70
- very low birthweight
 - multiple pregnancy 304
 - neonatal deaths 442
- vibroacoustic stimulation 96, 105
- viral infections, transplantation patients 169
- Virchow triad 135
- vitamin(s)
 - prenatal 21
 - toxicity 18
- vitamin C, iron absorption 15
- vitamin D 16, 17
 - supplementation 17
 - toxicity 18
- vitamin K neonatal deficiency 205
- vitronectin 134
- von Willebrand factor 119, 135
- warfarin 45
 - mechanical heart valve anticoagulation 149–150, 151
- weight, fetal
 - estimation 287
 - mild preeclampsia 273
- weight, maternal 8
 - energy supplementation 14
 - excessive gain 20
 - gain in pregnancy 9
 - pregnancy 9, 10–11
 - preterm delivery 10
 - protein supplementation 14
 - retention 11
 - target levels 19, 20
 - underweight 9–10, 20
 - see also* obesity
- white American women, weight retention 11
- white blood cells 347
- Wolff–Parkinson–White syndrome 152–153
- X-chromosomes, skewed inactivation 254
- X-linked disorders 61, 62, 254
- xylene 34
- zidovudine **244**, 247, 248, 249
- zinc toxicity 18
- zygosity 305

